News & Updates | The Sage Group

Sage Group News

Sage Represents BioHit Healthcare: Opportunity for Leadership in Nicotine-Free Smoking Cessation Usi

BioHit Healthcare has developed and gained approval in Europe for the Acetium® lozenge. This binds cigarette smoke-derived acetaldehyde...

G-MED, the Largest Online Global Medical Community Serving 1 Million Physicians and Growing!

London, 28 October 2019. G-Med is the largest Online Global Medical Community for >1,000,000 physicians, from over 120 countries...

OncoSec Announces $30 Million USD Strategic Investment at a Premium to Market by China Grand Pharmac

CGP Obtains a 12-Month Option to Offer to Acquire the Remaining Shares of OncoSec at the Greater of $4.50 Per Share or 110% of the Market...

WntResearch Increases Resources for Out-Licensing of Foxy-5

WntResearch and The Sage Group have initiated a collaboration to accelerate the process of identifying and engaging potential partners...

Sage Group Announces OncoSec Collaboration For TAVO™ Gene Therapy In Australia With Emerge Health

SAN DIEGO and PENNINGTON, N.J., May 29, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing...

Opportunity for Leadership in Epigenetic Control of Metastatic Cancer

Sage is representing EpiAxis Therapeutics. We are seeking strategic partners to license their novel technology for epigenetic control of...

OraMelts Drug Delivery Platform: Opportunity for Leadership in IntraOral Drug Delivery

The Sage Group is representing Quest Consumer Health Holdings, the owner of the OraMelts manufacturing facility and patent portfolio, in...

The Sage Group Client Delcath Announces Commercial Licensing Agreement for CHEMOSAT®

The Sage Group Client Delcath Announces Commercial Licensing Agreement for CHEMOSAT® 7 Year Agreement with medac to Maximize Potential of...